Menu Search
Equities

ABBVIE DRN

ABBV34:SAO

ABBVIE DRN

Actions
  • Price (BRL)62.52
  • Today's Change2.37 / 3.94%
  • Shares traded477.00
  • 1 Year change+49.21%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 19:53 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ABBV:NYQ since
announced		Transaction
value
Aliada Therapeutics IncAnnounced28 Oct 202428 Oct 2024Announced-8.62%1.40bn
Celsius Therapeutics IncDeal completed27 Jun 202427 Jun 2024Deal completed0.30%250.00m
Cerevel Therapeutics Holdings IncDeal completed06 Dec 202306 Dec 2023Deal completed18.73%8.70bn
ImmunoGen IncDeal completed30 Nov 202330 Nov 2023Deal completed23.94%10.22bn
Data delayed at least 15 minutes, as of Nov 21 2024 19:54 GMT.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Caixa DTVM SAas of 30 Jun 2024406.67k0.00%
BRAM - Bradesco Asset Management SA DTVMas of 30 Jun 202457.28k0.00%
Daycoval Asset Management Administra��o de Recursos Ltda.as of 30 Jun 20244.56k0.00%
XP Allocation Asset Management Ltda.as of 30 Jun 20242.03k0.00%
More ▼
Data from 30 Jun 2024 - 08 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.